This is a scientific update with no new binary catalyst — the Phase 2b data readouts in mid-2027 and late 2027 are the next major value inflection points. Monitor for any early efficacy signals or safety flags from the ongoing trials, but no immediate trading action is warranted.
Price Chart
Executive Summary
Kymera Therapeutics announced that KT-621 Phase 1b atopic dermatitis data will be presented at SID and ATS conferences, showing deep STAT6 degradation in skin, biomarker reductions, and clinical activity. Parallel Phase 2b trials in AD and asthma are ongoing with data expected by mid-2027 and late 2027, respectively. The press release contains no new financial data or regulatory milestones — it is a routine scientific update.
Key Facts
- KT-621 Phase 1b data featured in late-breaking oral presentation at SID 2026 (May 16) and oral presentation at ATS Respiratory Innovation Summit (May 16).
- New immunohistochemistry data show robust STAT6 degradation in epidermal keratinocytes and dermis after 4 weeks of treatment.
- Transcriptomic analyses revealed downregulation of AD-relevant gene signatures including Type 2 markers, epithelial hyperplasia, itch signaling, fibrosis, and broader inflammatory pathways.
- Parallel Phase 2b trials in atopic dermatitis and asthma are ongoing, with data expected by mid-2027 and late 2027, respectively.
- KT-621 is a first-in-class oral STAT6 degrader targeting IL-4/IL-13 signaling, the central driver of Type 2 inflammation.
Financial Impact
No financial data or guidance provided; pre-revenue clinical-stage company.
Risk Factors
- Phase 2b results may not replicate Phase 1b efficacy or safety profile.
- Competition from existing biologics (dupilumab) and other oral therapies in development for Type 2 inflammatory diseases.
- Clinical-stage biotech with no approved products or revenue; reliance on capital markets for funding.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295720 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 5, 2026 8w ago | 8-K | $105.48 $118.63 | ▲ +12.47% | ▲ +13.07% | $107.39 (+1.81%) |
Jul 8, 2026 12w ago | Insider Cluster | $114.16 $105.48 | ▲ +7.60% | ▲ +10.88% | $107.39 (+5.93%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jul 2, 2026 13w ago | Insider Cluster | $113.51 $107.01 | ▲ +5.73% | ▲ +5.31% | $107.39 (+5.39%) |
Jun 30, 2026 13w ago | 144 | $114.20 $105.25 | ▲ +7.84% | ▲ +5.65% | $107.39 (+5.96%) |
Jun 29, 2026 13w ago | 144 | $114.67 $110.05 | ▼ −4.03% | ▼ −3.00% | $107.39 (−6.35%) |
Jun 26, 2026 13w ago | Insider Cluster | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 26, 2026 13w ago | 144 | $109.32 $110.57 | ▼ −1.14% | ▼ −1.42% | $107.39 (+1.77%) |
Jun 24, 2026 14w ago | 144 | $116.46 $110.38 | ▼ −5.22% | ▼ −5.75% | $107.39 (−7.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access